(Ovarian Cancer) Efficacy of Niraparib Plus Bevacizumab?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
Niraparib Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
- October 8, 2019
- Reading time: 2 minutes
On August 29, 2019, Mansoor Raza Mirza published in the medical journal The Lancet a comparative efficacy study: "PARP inhibitor niraparib plus VEGF antibody bevacizumab in platinum-sensitive recurrent ovarian cancer — NSGO-AVANOVA2/ENGOT-ov24 Phase 1/2 trial results."
Trial Design
This Phase 1/2 trial enrolled 97 patients with platinum-sensitive recurrent ovarian cancer in a randomized controlled design:
- Niraparib + bevacizumab group: N=48
- Niraparib monotherapy group: N=49
Primary endpoint: progression-free survival (PFS). Secondary endpoint: disease control rate.
Efficacy Results
At a median follow-up of 16.9 months:
- Median PFS: Niraparib + bevacizumab: 11.9 months / Niraparib alone: 5.5 months
- The niraparib + bevacizumab group showed a 65% reduction in disease progression risk, with a hazard ratio of 0.35 — a statistically significant improvement.
Safety Profile
Grade 3 or higher adverse event rates:
- Niraparib + bevacizumab: 65% (N=31) / Niraparib alone: 45% (N=22)
Most common Grade 3 adverse events:
- Anemia: Niraparib + bevacizumab 15% / Niraparib alone 18%
- Thrombocytopenia: Niraparib + bevacizumab 10% / Niraparib alone 12%
- Hypertension: Niraparib + bevacizumab 21% / Niraparib alone 0%
No patients in either group died due to adverse events.
Conclusions
Based on the NSGO-AVANOVA2/ENGOT-ov24 results, Mansoor Raza Mirza concluded that PARP inhibitor niraparib plus VEGF antibody bevacizumab demonstrated significant improvement in progression-free survival in patients with platinum-sensitive recurrent ovarian cancer across various chemotherapy regimens.
Source: Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019 Aug 29.
Tags: #OvarianCancer
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4